NCT06984679

Brief Summary

It is aimed to reveal impairments regarding urinary incontinence, dyspnea, muscle strength, functional capacity or quality of life in children and adolescents with cystic fibrosis compared to healthy children and adolescents.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
10mo left

Started Sep 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress44%
Sep 2025Mar 2027

First Submitted

Initial submission to the registry

May 14, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 22, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

September 15, 2025

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2027

Expected
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 3, 2027

Last Updated

March 27, 2026

Status Verified

March 1, 2026

Enrollment Period

1.5 years

First QC Date

May 14, 2025

Last Update Submit

March 23, 2026

Conditions

Keywords

Cystic FibrosisUrinary IncontinenceDyspneaMuscle StrengthQuality of LifeExercise Test

Outcome Measures

Primary Outcomes (1)

  • Hand Grip Strength

    Grip strength will be measured using a dynamometer. Each hand will be tested three times, and the highest value will be recorded for both sides.

    through study completion, an average of 1 year

Secondary Outcomes (8)

  • Dyspnea score

    through study completion, an average of 1 year

  • Pulmonary Function Test Evaluation

    through study completion, an average of 1 year

  • Respiratory Muscle Strength Evaluation

    through study completion, an average of 1 year

  • Cough Strength Evaluation

    through study completion, an average of 1 year

  • Aerobic Exercise Capacity Evaluation

    through study completion, an average of 1 year

  • +3 more secondary outcomes

Study Arms (2)

Cystic Fibrosis Group

This group will consist of children and adolescents with cystic fibrosis.

Other: Physical Evaluations in Children with Cystic Fibrosis

Control Group

This group will consist of healthy children and adolescents.

Other: Physical Evaluations in Healthy Children

Interventions

In this study, dyspnea, functional capacity, muscle strength, urinary incontinence and quality of life will be evaluated in healthy children and adolescents. The data to be obtained from all these assessments will be made face to face within 45-60 minutes.

Control Group

In this study, dyspnea, functional capacity, muscle strength, urinary incontinence and quality of life will be evaluated in children and adolescents with cystic fibrosis. The data to be obtained through all these evaluations will be done face to face within 45-60 minutes.

Cystic Fibrosis Group

Eligibility Criteria

Age6 Years - 18 Years
Sexall
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

At least 25 patients with cystic fibrosis will be included in the main group and at least 25 healthy individuals will be included in the control group.

You may qualify if:

  • To be between the ages of 6-18
  • To have been diagnosed with cystic fibrosis
  • To be clinically stable for at least 3 weeks
  • To have the necessary cooperation for the measurements
  • To volunteer to participate in the study
  • To be between the ages of 6-18
  • To be in a similar average and ratio with the group of children and adolescents with cystic fibrosis in terms of age and gender
  • To have the necessary cooperation for the measurements
  • To volunteer to participate in the study

You may not qualify if:

  • Having any orthopedic, neurological, psychological or cardiovascular problem that may prevent the measurements from being performed in the last 6 months
  • Smoking or quitting smoking
  • Having any orthopedic, neurological, psychological or cardiovascular problem that may prevent the measurements from being performed in the last 6 months
  • Having any chronic disease
  • Smoking or quitting smoking

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Izmir Democracy University

Izmir, 35140, Turkey (Türkiye)

RECRUITING

Related Publications (3)

  • Tuğay, B. U., Arıkan, H., & Özçelik, U. (2004). Kistik fibrozisli çocuklarda pulmoner fonksiyonlar ve vücut kompozisyonu ile kas kuvveti arasındaki ilişki. Fizyoterapi ve Rehabilitasyon, 15(2), 47-54.

    BACKGROUND
  • Frayman KB, Kazmerski TM, Sawyer SM. A systematic review of the prevalence and impact of urinary incontinence in cystic fibrosis. Respirology. 2018 Jan;23(1):46-54. doi: 10.1111/resp.13125. Epub 2017 Jul 18.

    PMID: 28718995BACKGROUND
  • Heron J, Grzeda MT, von Gontard A, Wright A, Joinson C. Trajectories of urinary incontinence in childhood and bladder and bowel symptoms in adolescence: prospective cohort study. BMJ Open. 2017 Mar 14;7(3):e014238. doi: 10.1136/bmjopen-2016-014238.

    PMID: 28292756BACKGROUND

MeSH Terms

Conditions

Cystic FibrosisUrinary IncontinenceDyspnea

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, DiseasesUrination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsRespiration DisordersSigns and Symptoms, Respiratory

Study Officials

  • Gülşah Barğı, Assoc Prof

    Izmir Democracy University

    STUDY DIRECTOR
  • Yağmur Külekçi, PT

    Izmir Democracy University

    PRINCIPAL INVESTIGATOR
  • Gökçen Kartal Öztürk, Assoc Prof

    Ege University

    PRINCIPAL INVESTIGATOR
  • Ece Ocak, Dr

    Izmir City Hospital

    PRINCIPAL INVESTIGATOR
  • Kübra Özkaya, Dr

    Ege University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gülşah Barğı, Assoc Prof

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 14, 2025

First Posted

May 22, 2025

Study Start

September 15, 2025

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

March 3, 2027

Last Updated

March 27, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations